Cystoid macular edema with docetaxel chemotherapy and the fluid retention syndrome

Semin Ophthalmol. Jul-Sep 2007;22(3):151-3. doi: 10.1080/08820530701457373.

Abstract

Docetaxel (Taxotere) is an anticancer agent used to treat a wide range of malignancies including breast, lung, and prostate cancer. In this report, we describe a patient with bilateral vision loss due to cystoid macular edema (CME) associated with docetaxel therapy. This report documents for the first time the optical coherence tomography (OCT) findings of CME despite the lack of leakage with flourescein angiography and its association with the Fluid Retention Syndrome (FRS). Successful management of CME with oral acetazolamide is also discussed.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetazolamide / administration & dosage
  • Acetazolamide / therapeutic use
  • Administration, Oral
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / secondary
  • Diuretics / administration & dosage
  • Diuretics / therapeutic use
  • Docetaxel
  • Edema / chemically induced*
  • Edema / drug therapy
  • Female
  • Fluorescein Angiography
  • Humans
  • Macular Edema / chemically induced*
  • Macular Edema / diagnosis
  • Macular Edema / drug therapy
  • Middle Aged
  • Taxoids / adverse effects*
  • Taxoids / therapeutic use
  • Tomography, Optical Coherence

Substances

  • Antineoplastic Agents
  • Diuretics
  • Taxoids
  • Docetaxel
  • Acetazolamide